X Financial (NYSE: XYF), a Shenzen, China-based technology-driven personal finance company, announced a commitment to invest in an aggregate amount of US$10m in a venture capital fund managed by Dragonfly Ventures II, L.P. for blockchain industry investment opportunities.
YishengBio Co., Ltd., a Beijing, China-based fully integrated biopharmaceutical company, closed a US$130m Series B funding round.
WuXi Diagnostic Investment (Cayman) Limited, a Shangai, China-based diagnostics company, completed US$150m in series B funding.
AnchorDx Medical Co., Ltd., a Guangzhou, China-based developer of DNA methylation NGS products, closed a USD40m Series C financing.
Regor Therapeutics, a Shangai, China-based clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, closed a $90m Series B financing.
Hangzhou Sciwind Biosciences Co., Ltd., a Hangzhou, China-based clinical-stage biopharmaceutical company focusing on research and development of innovative biologics, closed a US$37M series B financing.
Neurophth Biotechnology Ltd., a Wuhan, China-based fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, closed a RMB 400m ($61.9m USD) Series-B financing.
Drug Farm, a Shangai, China- and Guilford, MA-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, completed financing totaling $56m USD.
Whales English, a Beijing, China-based brand in online K-12 English group classes, completed a series B+ round of funding.
Anticancer Bioscience (ACB), a Chengdu, China-based pioneers in synthetic lethal approaches to precision oncology, closed an additional financing round, raising CNY63m (approx. USD10m).
Chinese venture capital firm Qiming Venture Partners held the final close of its RMB Fund VI at RMB 2.852 billion.
Visen Pharmaceuticals, a Shangai, China-based biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, closed a $150m Series B financing.
Zuoyebang, a Beijing, China-based online after school education startup, raised over US$1.6 Billion in its Series E+ financing.
iQIYI Inc. (NASDAQ: IQ), a Beijing, China-based online entertainment service company, recently completed a multi-hundred million RMB Series B funding round for its virtual reality (VR) division iQIYI Intelligent.
Flexiv Ltd., a global general-purpose robotics company, closed an over 100m USD Series B funding round.